Disclosed is the use of a pyrimidylaminobenzamide which is 4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide (nilotinib) in the preparation of a medicament for the treatment of proliferative disorders and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the medicament is formulated for administration of 600 mg of the pyrimidylaminobenzamide once daily just before bedtime (QHS). In particular the medicament is useful in treating Philadelphia positive leukaemia (Ph+ ALL) and Chronic myelogenous (or myeloid) leukemia (CML).
